Get the Stockscreener App
128.00
1.07%
1.36
After Hours:
128.45
0.45
+0.35%
Biogen Inc stock is traded at $128.00, with a volume of 3.24M.
It is up +1.07% in the last 24 hours and up +1.92% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$126.64
Open:
$133
24h Volume:
3.24M
Relative Volume:
2.23
Market Cap:
$18.76B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
12.64
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
-3.46%
1M Performance:
+1.92%
6M Performance:
-11.07%
1Y Performance:
-39.96%
1-Day Range:
$127.24
$135.43
1-Week Range:
$125.97
$135.43
52-Week Range:
$110.03
$219.44
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
128.00 | 18.56B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
740.07 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.74 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
189.02 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
113.74 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
78.12 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus
Biogen to Report Second Quarter 2025 Financial Results July 31, 2025 - Biogen
TD Asset Management Inc Sells 71,330 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen stock holds steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada
AAIC 2025: Leqembi rides on real-world, subq autoinjector data - BioWorld MedTech
Biogen stock price target lowered to $144 at Morgan Stanley By Investing.com - Investing.com Canada
Biogen Edges Closer To Growth On Strong Q2 - insights.citeline.com
Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth - MSN
Biogen stock holds steady as Oppenheimer reiterates Outperform rating - Investing.com Australia
Biogen's Q2 2025 Earnings Call: Key Contradictions in LEQEMBI's Market Share, Pipeline Strategy, and Alzheimer’s Diagnostics - AInvest
Biogen plans to act on $8B to $10B in deal capacity - The Business Journals
Skandinaviska Enskilda Banken AB publ Has $6.39 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen signals Leqembi sales gaining momentum, lifts profit forecast - Reuters
Biogen’s Litifilimab Study: A Long-Term Hope for Lupus Treatment - TipRanks
Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises - Investing.com Australia
Why Is Biogen Stock Gaining Thursday?Biogen (NASDAQ:BIIB) - Benzinga
UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up - Yahoo Finance
Biogen Lifts Profit Guidance on Sales of Alzheimer’s Drug - Bloomberg
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Biogen raises annual profit forecast on strong demand for rare disease drugs - MarketScreener
Biogen Q2 2025 slides: Raised guidance, pipeline expansion drive stock higher - Investing.com India
Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook - MSN
Biogen Exceeds Q2 Revenue Expectations, Raises Full-Year Guidance - AInvest
Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen Q2 Results Top Estimates; Boosts FY25 Outlook - Nasdaq
Seizert Capital Partners LLC Acquires 10,786 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Letko Brosseau & Associates Inc. Sells 3,972 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Reports Bullish Q2 - TradingView
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates - Yahoo.co
Biogen raises annual profit estimates on strong demand for rare disease drugs - 1470 & 100.3 WMBD
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up - Yahoo Finance
Biogen stock rises on Q2 beat (BIIB:NASDAQ) - Seeking Alpha
Biogen (BIIB) Enhances 2025 Financial Outlook with Revised Guidance - GuruFocus
Biogen Inc (BIIB) Q2 2025 Earnings: Revenue Surges to $2.6 Billion, GAAP EPS Hits $4.33, Both Exceed Estimates - GuruFocus
Biogen earnings beat by $1.48, revenue topped estimates - Investing.com Canada
Biogen's Q2 revenue up by 7% to $2.6 billion - breakingthenews.net
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 - TradingView
Biogen Lifts Profit Guidance on Rising Sales of Alzheimer’s Drug - Bloomberg
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA - Yahoo Finance
Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market - 富途牛牛
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease - ACN Newswire
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
Stevens Capital Management LP Takes $395,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s BIIB122 Study: A New Hope for LRRK2-Associated Parkinson’s Disease - TipRanks
Eisai, Biogen present data on lecanemab subcutaneous autoinjector - Investing.com Australia
Lecanemab real-world study shows promising results in early Alzheimer’s By Investing.com - Investing.com South Africa
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 - Biogen
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 – Company AnnouncementFT.com - Financial Times
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm - ACCESS Newswire
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):